Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NUC-7738 |
Synonyms | |
Therapy Description |
NUC-7738 is a prodrug of 3’-deoxyadenosine, which potentially decreases beta-catenin signaling and tumor cell proliferation and increases tumor cell apoptosis (PMID: 36520954, PMID: 36417756). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NUC-7738 | NUC7738|NUC 7738 | NUC-7738 is a prodrug of 3’-deoxyadenosine, which potentially decreases beta-catenin signaling and tumor cell proliferation and increases tumor cell apoptosis (PMID: 36520954, PMID: 36417756). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03829254 | Phase Ib/II | NUC-7738 NUC-7738 + Pembrolizumab | A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | Recruiting | GBR | 0 |